We identified three common signature genes (PLCXD3, CCL19, and PKD2), co-regulated pathways, and shared immune features of NAFLD and AS, which might provide novel insights into the molecular mechanism of NAFLD complicated with AS. The gene discussed is CCL19; the disease is metabolic dysfunction-associated steatotic liver disease.